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DNA microarrays have tremendous promise for the development of personalized medicine, allowing physicians to select specific treatments to maximize therapeutic efficacy and to minimize side effects, based on an individual's unique genetic profile. They allow for the simultaneous testing of thousands of DNA sequences, and the AmpliChip CYP450 test employs this technology for cytochrome P450 (CYP) 2D6 and CYP2C19 genotyping. Isoenzymes coded by these genes metabolize many prescribed drugs. Jose de Leon, MD, and colleagues identified these alleles and phenotypes in 4,532 psychiatric patients. The prevalence of CYP2D6 poor metabolizers was 7.6% (8.2% in Caucasians, 1.8% in the African Americans). The prevalence of CYP2D6 ultrarapid metabolizers was 1.5% (1.5% in Caucasians, 2.0% in African Americans). The prevalence of CYP2C19 poor metabolizers was 2.0% (2.2% in Caucasians, 4.0% in African Americans). De Leon and colleagues propose a numeric system for expression of CYP2D6 and CYP2C19 enzyme activity to aid clinicians in determining treatment strategy for patients receiving therapeutics that are metabolized by the CYP2D6 or CYP2C19 gene products. DNA technology is rapidly becoming more powerful, and its costs are rapidly decreasing. However, the practical impact of such technology has been relatively limited to date. One exception is the gene testing for cytochrome isoenzymes involved in metabolizing drugs, which does have some impact in everyday clinical practice. This article is helpful in determining how common slow and rapid metabolizers of CYP gene products are, and how to use this information in determining treatment options.
Alan D. Feiger, MD, and colleagues compared the efficacy and safety of desvenlafaxine succinate versus placebo in treating major depressive disorder (MDD) in a randomized, double-blind study of adult patients with MDD. In this study. the primary analysis did not show significant differences between desvenlafaxine and placebo; discontinuations due to AEs associated with the desvenlafaxine dose range may have contributed to the lack of statistical separation. Discontinuation rates due to adverse events (AEs) were 12% and 3% for desvenlafaxine and placebo, respectively. On secondary measures, differences in week 8 observed cases and at the final evaluation were significant for the primary measures. The most frequently reported AE associated with desvenlafaxine was nausea (36% vs 9%). Thus, in this single trial, avoiding variations in first pass liver metabolism did not eliminate the side effects of the active metabolite.
Dyke-Davidoff-Masson syndrome, or cerebral hemiatrophy, is a pre-or perinatally acquired entity and is characterized by predominantly neurologic symptoms, such as seizures, facial asymmetry, contralateral hemiplegia, and mental retardation. Benedikt Amann, MD, PhD, and colleagues report the first case of left cerebral hemiatrophy and a late onset of treatment-resistant schizoaffective disorder after a stressful life event. The patient finally responded well to clozapine. The clinical history and results from structural neuroirnaging are highlighted to discuss the possible developmental bias for psychotic disorders. Thus, psychotic symptoms may occur within the context of a complex neurologic presentation and having a unique developmental trajectory.
New technologies do have the potential to advance human health as well as to lead to unexpected forms of human suffering. DNA microarrays do have tremendous promise for the development of personalized medicine.
Finally, I would like to express my profound thanks to all of our peer reviewers, listed on the following page. The hard work of these talented and dedicated individuals has allowed the journal to experience a dramatic improvement not only in impact factor (3.409 for Psychiatry and 2.746 for Clinical Neurology), but also in readership interest. CNS
